Catalyst, Wyeth in Factor VIIa deal

Catalyst BioSciences Inc. (South San Francisco, Calif.) granted Wyeth (NYSE:WYE) exclusive, worldwide rights to develop and commercialize CB 813, a recombinant human coagulation Factor VIIa that is in preclinical development to treat and prevent acute bleeding in hemophilia patients. The companies also entered a two-year research agreement for additional Factor VIIa compounds. Catalyst will discover the compounds and conduct preclinical development, and Wyeth will have exclusive, worldwide development and commercialization rights. ...